Current treatment paradigms for locally advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue SUPPL. 2, 2007, Pages

  Rigas, James R ^a   Kelly, Karen ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

Chemotherapy; Cisplatin; Consolidation; Docetaxel; Etoposide; Non small cell lung cancer; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; VINBLASTINE; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GRANULOCYTE COLONY STIMULATING FACTOR; MITOMYCIN; PEMETREXED; VASCULOTROPIN INHIBITOR; VINDESINE;

ADVANCED CANCER; ANEMIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DRUG DOSE ESCALATION; ESOPHAGITIS; HUMAN; INOPERABLE CANCER; LUNG FUNCTION TEST; LUNG NON SMALL CELL CANCER; MICROMETASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION INJURY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; ADJUVANT THERAPY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER MORTALITY; CANCER RELAPSE; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GRANULOCYTOPENIA; LUNG RESECTION; LUNG TOXICITY; LYMPH NODE METASTASIS; MEDIASTINUM CANCER; MEDIASTINUM LYMPH NODE; META ANALYSIS; MORBIDITY; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURGICAL MORTALITY; SYSTEMATIC REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING;

EID: 34250855750     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000269735.21209.bc     Document Type: Conference Paper

References (56)

1. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-462.
2. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
3. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727.
4. Douillard J, Rosell R, De Lena M, et al. Impact of radiation on survival after complete resection of non-small-cell lung cancer: descriptive analysis in the randomized adjuvant chemotherapy trial, ANITA 1. Int J Radiat Oncol Biol Phys 2006;66 (3 Suppl.):S2.
5. Gumerlock PH, Mack PC, Manorek GH, et al. Bcl2 phosphorylation and p27 induction as potential p53-independent mechanisms of apoptotic responses to taxanes in non-small cell lung carcinoma (NSCLC). Proc Am Assoc Cancer Res 1999; 40:739. Abstract 4879.
6. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991;83:288-291.
7. Hill BT, Whelan RD, Shellard SA, et al. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 1994;12:169-182.
8. van Ark-Otte J, Samelis G, Rubio G, et al. Effects of tubulininhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 1998;5: 249-255.
9. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747-2755.
10. Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995;22 (Suppl. 4):3-16.
11. Mason K, Staab A, Hunter N, et al. Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 2001;18:599-606.
12. Grant DS, Williams TL, Zahaczewsky M, et al. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003;104:121-129.
13. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
14. Gandara DR, Vokes E, Green M, et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000;18:131-135.
15. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
16. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158.
17. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-680.
18. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215.
19. Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006;1:611-621.
20. Swiss Institute for Applied Cancer Research. Chemotherapy with or without radiation therapy before surgery in treating patients with stage IIIA non-small cell lung cancer (NIH web site). October 2006. Available at: http://www.clinicaltrials.gov/ct/show/NCT00030771?order=1. Accessed: 1 November 2006.
21. Radiation Therapy Oncology Group. Cisplatin and docetaxel with or without radiation therapy in treating patients who are undergoing surgery for newly diagnosed stage III non-small cell lung cancer (NIH web site). December 2006. Available at: http://www.clinicaltrials.gov/ct/show/NCT00113386?order=1. Accessed: 13 January 2007.
22. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003;21:1752-1759.
23. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006;94:1099-1106.
24. Van Zandwijk N, Smit EF, Kramer GW, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000;18:2658-2664.
25. Biesma B, Manegold C, Smit HJM, et al. Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer (EORTC 08984). Eur J Cancer 2006;42:1399-1406.
26. Pezzetta E, Stupp R, Zouhair A, et al. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC. Eur J Cardiothorac Surg 2005;27:1092-1098.
27. Van Kooten M, Rosenberg M, Orlando M, et al. Neoadjuvant chemotherapy with gemcitabine and cisplatin in stage IIIA/B non-small cell lung cancer. Invest New Drugs 2002;20:439-446.
28. Yang CH, Tsai CM, Wang LS, et al. Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer. Br J Cancer 2002;86:190-195.
29. Grossi F, Pennucci MC, Serrano J, et al. Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer. Anticancer Res 2002;22:3519-3524.
30. Van Meerbeeck JP, Kramer G, Van Schil PE, et al. A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941). J Clin Oncol 2005;23 (Suppl.):7015.
31. Katayama H, Ueoka H, Kiura K, et al. Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. Br J Cancer 2004;90:979-984.
32. Kim S, Sohn H, Suh C, et al. Neoadjuvant weekly paclitaxel/cisplatin chemotherapy (WTP) with concurrent thoracic chemoradiation followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NCLC): Phase II study. J Clin Oncol 2006;24 (Suppl.):17036.
33. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stage IIIA(N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-1892.
34. Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 2005;23 (Suppl.):7014.
35. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
36. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
37. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003; 22:621. Abstract 2499.
38. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87-98.
39. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancérologie NPC 95-01 study. J Clin Oncol 2005;23:5910-5917.
40. Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004;18:CD002140.
41. Clamon G, Herndon J, Cooper R, et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:4-11.
42. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): initial analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 2004;23:616. Abstract 7005.
43. Gervais R, Ducolone A, Lechevalier T, et al. Conventional radiation (RT) with daily carboplatin (Cb) compared to RT alone after induction chemotherapy (ICT) [vinorelbine (Vr)-cisplatin (P)]: final results of a randomized phase III trial in stage III unresectable non small cell lung (NSCLC) cancer. Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT. J Clin Oncol 2005;23 (Suppl.):7016.
44. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005;23:5883-5891.
45. Fournel P, Vergnenégre A, Robinet G, et al. Induction (ICT) or consolidation chemotherapy (CT) with cisplatin (C) and paclitaxel (P) plus concurrent chemo-radiation (CT/TRT) with cisplatin and vinorelbine (V) for unresectable non-small cell lung cancer (NSCLC) patients (pts): randomized phase II trial GFPC-GLOT-IFCT 02-01. J Clin Oncol 2006;24 (Suppl.):7048.
46. Colin P, Jovenin N, Ganem G, et al. Effect of paclitaxel-carboplatin (PC) consolidation chemotherapy after weekly PC concurrent chemo-radiotherapy (CCR) for patients with locally advanced non-small cell lung cancer (LA-NSCLC): 3-year definitive results of the B001-phase III GERCOR-study. J Clin Oncol 2006;24 (Suppl.):7112.
47. Albain KS, Crowley JJ, Turrisi AT, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002;20:3454-3460.
48. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21:2004-2010.
49. Lara P, Chanski K, Gaspar L, et al. Consolidation docetaxel (D) following concurrent chemoradiotherapy (chemoRT) in stage IIIB non-small cell lung cancer (NSCLC): updated five-year survival results from Southwest Oncology Group trial S9504. Lung Cancer 2005; 49(Suppl. 2). Abstract PD-075.
50. Sekine I, Nokihara H, Sumi M, et al. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 2006;1:810-815.
51. Kelly K, Gaspar LE, Chansky K, et al. Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. J Clin Oncol 2005;23 (Suppl.):7058.
52. Bedano PM, Neubauer M, Ansari R, et al. Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): an interim toxicity analysis of consolidation therapy. J Clin Oncol 2006;24 (Suppl.):7043.
53. Southwest Oncology Group. Combination chemotherapy, radiation therapy, and bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery (NIH web site). December 2006. Available at: http://www.clinicaltrials.gov/ct/show/NCT00334815?order=3. Accessed: 13 January 2007.
54. Southwest Oncology Group. Docetaxel, cetuximab, and radiation therapy in treating patients with stage III non-small cell lung cancer (NIH web site). December 2006. Available at: http://www.clinicaltrials.gov/ct/show/NCT00288054? order=2. Accessed: 13 January 2007.
55. Cancer and Leukemia Group B. Pemetrexed disodium, carboplatin, and radiation therapy with or without cetuximab in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery (NIH web site). December 2006. Available at: http://clinicaltrials.gov/ct/show/NCT00117962. Accessed: 13 January 2007.
56. Norris Cotton Cancer Center, Dartmouth Medical Center. A national web-based randomized phase III study of erlotinib or placebo following concurrent docetaxel, carboplatin, and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer (Norris Cotton Cancer Center web site). Available at: http://www.cancer.dartmouth.edu/clinicaltrials/trials/ D0410.shtml 2005. Accessed: 1 November 2006.